^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET-targeted antibody-drug conjugate

    Related drugs:
    1m
    Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial. (PubMed, JTO Clin Res Rep)
    Teliso-V monotherapy 1.9 mg/kg elicited durable responses, irrespective of the type of previous therapy received, and maintained a manageable safety profile in patients with c-Met protein overexpressing EGFR wild-type, nonsquamous NSCLC. NCT03539536.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR wild-type • MET overexpression
    |
    Emrelis (telisotuzumab vedotin-tllv)
    1m
    Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=500, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | N=155 --> 500 | Trial completion date: Apr 2029 --> Jun 2031 | Trial primary completion date: Apr 2027 --> Jun 2031
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed
    2ms
    A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    2ms
    Neurotrophic Keratitis Associated With Telisotuzumab Vedotin: A Case Report. (PubMed, Cornea)
    This report describes the first documented case of NK associated with Teliso-V therapy. The temporal association between Teliso-V exposure, bilateral corneal hypoesthesia, persistent epithelial defects, and concurrent peripheral neuropathy suggests a potential neurotoxic mechanism related to the drug's monomethyl auristatin E payload. Clinicians should maintain a high index of suspicion for NK in patients receiving ADCs who present with painless visual decline and corneal epithelial disease. Early diagnosis and prompt treatment with cenegermin may facilitate corneal healing and prevent vision-threatening complications.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    Emrelis (telisotuzumab vedotin-tllv)
    2ms
    A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=700, Recruiting, AbbVie | Trial completion date: May 2029 --> Mar 2030
    Trial completion date
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)
    2ms
    A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=700, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)
    2ms
    PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC (clinicaltrials.gov)
    P1, N=396, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial
    |
    Ameile (aumolertinib)
    2ms
    EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov)
    P1, N=167, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=403 --> 167
    Enrollment closed • Enrollment change • First-in-human
    |
    EGFR wild-type
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • 5-fluorouracil • leucovorin calcium • tilatamig samrotecan (AZD9592)
    2ms
    A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2/3, N=900, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • telisotuzumab adizutecan (ABBV-400)
    2ms
    A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    |
    Keytruda (pembrolizumab) • cisplatin • Tagrisso (osimertinib) • carboplatin • Ivesa (firmonertinib)
    3ms
    AndroMETa-CRC-064: A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=74, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=460 --> 74 | Trial completion date: Oct 2028 --> Aug 2027 | Trial primary completion date: Oct 2028 --> Aug 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Adverse events
    |
    telisotuzumab adizutecan (ABBV-400)